-
0.4% Trypan Blue Solution: Practical Guide
2026-09-23
0.4% Trypan Blue Solution provides a rapid membrane-integrity method for cell viability measurement, cell counting, and live/dead cell discrimination. It is appropriate for research workflows and cytotoxicity assay readouts, but it should not be treated as a diagnostic method or as a standalone test for apoptosis and necrosis.
-
Reparixin and the IL-8–CXCR1 Axis
2026-09-22
A translational framework for using Reparixin, a CXCR1/2 inhibitor, to connect IL-8 signaling with neutrophil biology, tissue injury, and emerging microbe–tumor research.
-
MRSA EVs Drive IL-8–Dependent OSCC Growth
2026-09-21
This study identifies extracellular vesicles released by methicillin-resistant Staphylococcus aureus as active modulators of oral squamous cell carcinoma, rather than passive indicators of infection. By combining EV comparison, uptake studies, pathway perturbation, and in vivo loss-of-function experiments, the authors connect MRSA EV proteins with an ERK/c-Jun–IL-8–CXCR1–JAK/STAT5A signaling axis that promotes tumor-cell proliferation.
-
Morning Endurance Training Improves Mouse Adaptation
2026-09-21
Hesketh and colleagues show that endurance training during the early active phase produces faster performance gains in female mice than training during the late active phase. The study separates time-of-day effects on acute endurance capacity from the efficiency of long-term adaptation and identifies skeletal-muscle oxidative and contractile remodeling as relevant correlates.
-
5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine
2026-09-20
Use this DMSO-compatible α2-adrenergic receptor agonist to separate direct tumor-cell effects from immune-mediated control. The workflow connects receptor pharmacology, localized hydrogel delivery, and CD8+ T-cell assays for post-surgery osteosarcoma recurrence treatment research.
-
Linarin, Cyclin A2, and NSCLC Cell-Cycle Arrest
2026-09-19
A 2026 study identifies the Herba Patriniae component Linarin as an inhibitor of NSCLC cell growth that promotes G0/G1 arrest, senescence, and apoptosis in both p53-wild-type and p53-null models. Its combination of network pharmacology, EdU-based proliferation analysis, phenotypic assays, docking, and immunoblotting links these effects particularly to reduced CCNA2, CCNB1, and CHEK1 signaling.
-
RIPA Lysis Buffer Strong for BAT Protein Assays
2026-09-19
RIPA Lysis Buffer Strong combines aggressive detergent-mediated lysis with inhibitor-free flexibility for customized BAT, cell, and tissue protein workflows. This guide shows how to adapt it for Western blotting, immunoprecipitation, ELISA, and kinase-focused validation while avoiding common compatibility problems.
-
BODIPY 581/591 C11 for Lipid Peroxidation
2026-09-18
BODIPY 581/591 C11 converts membrane lipid oxidation into a quantitative red-to-green fluorescence ratio for live-cell and model-membrane experiments. Its ratiometric design supports oxidative stress measurement, antioxidant capacity evaluation, and mechanistic studies of endothelial ferroptosis with fewer loading and photobleaching confounders than single-channel readouts.
-
Reparixin: Reliable CXCR1/2 Assay Design
2026-09-18
This scenario-driven guide explains how Reparixin (SKU A3752) can improve mechanistic interpretation in neutrophil migration, proliferation, and cytotoxicity workflows. It covers assay compatibility, fresh-solution handling, controls, vendor selection, and the limits of extending CXCL8–CXCR1 evidence into tumor models.
-
PSI-7977: A Redox-Aware Assay Design Guide
2026-09-17
PSI-7977 can be studied more rigorously when compound identity, redox state, and cell-death phenotypes are separated. This guide connects its nucleotide-analog pharmacology with the BAP1–SLC7A11–NADPH framework to improve assay interpretation without overstating evidence.
-
Cisplatin Workflows for Cancer Research
2026-09-17
Build reproducible CDDP experiments around fresh preparation, dose–response design, DNA-damage readouts, and apoptosis validation. This guide connects Cisplatin treatment with cancer stem cell biology, chemotherapy resistance studies, and tumor growth inhibition in xenograft models.
-
Reversine: Practical Aurora Kinase Inhibitor Workflow
2026-09-16
Reversine (SKU A3760) is an Aurora kinase inhibitor for investigating mitotic regulation, cancer cell proliferation inhibition, and apoptosis-related phenotypes in cell and animal research models. It should be used as a research reagent with solvent, storage, and assay controls; it is not intended for diagnostic, therapeutic, or other medical use.
-
Hexose Diphosphate: Applied Metabolic Workflows
2026-09-15
Use hexose diphosphate to connect carbohydrate-phosphate metabolism with ATP balance, ischemia models, and carefully controlled inflammation assays. This workflow-focused guide emphasizes water-based preparation, time-resolved metabolic measurements, and the limits of translating findings from phosphoenolpyruvate research.
-
Biotin-XX Tyramide Reagent for Cell-Surface TSA
2026-09-15
Biotin-XX Tyramide Reagent combines HRP-driven signal amplification with a membrane-impermeant design for selective cell-surface labeling in tissue sections and cells. This article translates a Drosophila stem-cell migration study into practical immunohistochemistry and in situ hybridization assay choices, with workflow parameters and troubleshooting guidance.
-
NF-κB–YAP–NLRP3 Control of Colitis Pyroptosis
2026-09-14
A 2026 study identifies an epithelial NF-κB p65–LATS1–YAP–NLRP3 axis that links inflammatory signaling to GSDMD-dependent pyroptosis in ulcerative colitis. By combining epithelial-cell assays, DSS colitis, GSDMD knockout mice, YAP overexpression, nucleoplasmic separation, and chromatin immunoprecipitation, the work positions YAP loss as a key step connecting NF-κB activation with colonic barrier injury.